Platinum and palladium derivatives for chemotherapy studies.
Analogues of cis-dichlorodiammineplatinum(II) were prepared in which substituted pyridines (A), 1-(4-aminobenzylidene)indene (B), or DL-3,5,3'5'-tetraoxo-1,2-dipiperazinopropane (ICRF-159) was used in place of ammonia, and in some cases platinum(IV) or palladium(II) was used in place of the platinum(II). Both platinum complexes with ICRF-159 were active against leukemia 1210, but none of the others produced significant life extension following a single ip dose of 400 mg/kg. Attempts to prepare complexes of ICRF-159 with Zn(II), Mn(II), and Cr(III) were unsuccessful, but there were indications of complex formation with CuCl2 and with NiCl2.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D002945:Cisplatin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D009944:Organoplatinum Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D010165:Palladium / Q000494:pharmacology*
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D009944:Organoplatinum Compounds; D010165:Palladium; D002945:Cisplatin